We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NCKL:IDXPT Trimegah Bangun Persada Tbk Analysis

Data as of 2026-05-24 - not real-time

IDR 855.00

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

PT Trimegah Bangun Persada is trading at IDR 855, well below its 20‑day (1009.75), 50‑day (1112.6) and 200‑day (1143.38) moving averages, indicating a pronounced bearish technical backdrop. However, the RSI of 31.7 suggests the stock is oversold, while the MACD remains in a bearish zone with a negative histogram, and volume is on an increasing trend, hinting at potential short‑term accumulation. Fundamentally the company shines: revenue grew 9.7% YoY, margins are robust (gross 31.6%, operating 29.2%, profit 27.5%), and ROE stands at a healthy 25.3%. The valuation is attractive with a trailing PE of 6.75, a DCF‑derived fair value of IDR 970.7 and an implied upside of over 85% versus the current price. Dividend sustainability looks solid, given a 3.55% yield, a modest payout ratio of 24% and strong cash flow generation. The main headwinds are the high leverage (debt‑to‑equity ~23.7) and elevated volatility (64% 30‑day), which temper the bullish outlook despite a consensus strong‑buy rating and target prices near IDR 1,550‑1,580.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Oversold RSI indicating potential bounce
  • Bearish MACD and price below key moving averages
  • Increasing volume suggesting accumulation

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong earnings growth and high profitability margins
  • Attractive valuation metrics (low PE, high upside)
  • Sustainable dividend with low payout ratio

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Long‑term demand for nickel and strategic mining assets
  • Robust ROE and cash flow generation supporting growth
  • Analyst consensus strong‑buy and high target price multiples

Key Metrics & Analysis

Financial Health

Revenue Growth9.70%
Profit Margin27.55%
P/E Ratio6.7
ROE25.31%
ROA8.76%
Debt/Equity23.67
P/B Ratio1.5
Op. Cash FlowIDR7476.5B
Free Cash FlowIDR3390.0B

Technical Analysis

TrendBearish
RSI31.7
SupportIDR 775.00
ResistanceIDR 1,160.00
MA 20IDR 1,009.75
MA 50IDR 1,112.60
MA 200IDR 1,143.38
MACDBearish
VolumeIncreasing
Fear & Greed Index91.61

Valuation

Fair ValueIDR 970.73
Target PriceIDR 1,583.67
Upside/Downside85.22%
GradeUndervalued
TypeBlend
Dividend Yield3.55%

Risk Assessment

Beta1.02
Volatility64.18%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.